All In Biotech

Drug Trial Radar · NCT06690177

Controlled Study, Performed to Evaluate the Safety and Efficacy of EscharEx and Its Placebo (Gel Vehicle) Compared to Non-surgical Standard of Care in Participants With Venous Leg Ulcers (VLU)

A Multicenter, Prospective, Randomized, Placebo and Non-Surgical Standard of Care (NSSOC) Controlled Study, Performed to Evaluate the Safety and Efficacy of EscharEx and Its Placebo (Gel Vehicle) Compared to NSSOC in Participants With Venous Leg Ulcers (VLU)

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

45

Planned (sponsor's estimate)

Start

Jan 10, 2027

Primary completion

Nov 4, 2028

Study completion Jan 16, 2029

Sponsor

Lead sponsor
MediWound LtdIndustry
Sponsor type
Industry
First posted
Nov 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objectives of this study are: * To evaluate the safety of EscharEx and its placebo Gel Vehicle compared to non-surgical standard of care (NSSOC) * To assess the efficacy of EscharEx (EX-03 5% formulation) compared to placebo control and compared to NSSOC.

Conditions

  • Venus Leg Ulcers

Interventions

  • EscharEx (EX-03)Drug

    a sterile lyophilized powder containing a concentrate of proteolytic enzymes enriched in bromelain (anacaulase-bcdb). The powder and sterile water are mixed to form a gel prior to application on the wound area.

  • Placebo (Gel vehicle)Drug

    A sterile powder containing excipients only (no proteolytic enzymes). The powder and sterile water are mixed to form a gel prior to application on the wound area

  • Non-surgical standard of care (NSSOC)Other

    Various dressings and Collagenase

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence (number of patients) of systemic and local adverse events (AEs) throughout the trialTime frame: Throughout the study (week 2- week 17)
  2. Number of patients with Clinically significant changes in vital signs during the Daily Visits Period,Time frame: Weeks 2-3 (14 days)
  3. Number of patients with Clinically significant changes in clinical laboratory parametersTime frame: Weeks 2-3 (14 days)
  4. Time to complete wound closureTime frame: Weeks 2-17
  5. Incidence of complete wound closureTime frame: 2-17 weeks

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Nova Medical Research

    Maimi, Florida

  • Wojskowy Instytut Medyczny

    Warsaw, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.